We are live on ! Find out more
LRMR icon

Larimar Therapeutics

3.27 USD
+0.28
9.36%
At close Updated Nov 18, 10:16 AM EST
1 day
9.36%
5 days
21.11%
1 month
54.25%
3 months
-19.46%
6 months
0.93%
Year to date
-5.76%
1 year
-3.54%
5 years
-68.31%
10 years
-92.39%
 

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Employees: 71

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 25%
Neutral 62.5%
Negative 12.5%
Neutral
GlobeNewsWire
2 days ago
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2026 operating and financial results.
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
Neutral
GlobeNewsWire
8 days ago
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia (FA).
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich's Ataxia
Neutral
GlobeNewsWire
12 days ago
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich's ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10–13, 2026, in Atlanta, Georgia.
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Neutral
GlobeNewsWire
13 days ago
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Positive
MarketBeat
1 month ago
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Negative
Zacks Investment Research
1 month ago
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Neutral
GlobeNewsWire
1 month ago
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar's Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Positive
Zacks Investment Research
2 months ago
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Neutral
GlobeNewsWire
3 months ago
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Neutral
PRNewsWire
3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Price charts implemented using Lightweight Charts™